Arch Biopartners Ownership

Stocks Canada . 
Stock . Arch Biopartners
ARCH Stock  CAD 1.95  0.01  0.51%   
Arch Biopartners holds a total of 64.94 Million outstanding shares. Arch Biopartners shows 19.86 percent of its outstanding shares held by insiders and 0.0 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
 
Shares in Circulation  
First Issued
1998-03-31
Previous Quarter
62.5 M
Current Value
62.8 M
Avarage Shares Outstanding
39.1 M
Quarterly Volatility
21 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Some institutional investors establish a significant position in stocks such as Arch Biopartners in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Arch Biopartners, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Dividend Paid And Capex Coverage Ratio is likely to drop to -253.52 in 2024. Common Stock Shares Outstanding is likely to drop to about 41.8 M in 2024. Net Loss is likely to drop to about (1.3 M) in 2024.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arch Biopartners. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

Arch Stock Ownership Analysis

About 20.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.03. Arch Biopartners last dividend was issued on the 13th of September 2000. The entity had 1:3 split on the 25th of November 2003. Arch Biopartners Inc., a biotechnology company, develops technologies for improving the health of patients. In addition, the company develops Borg, a Peptide-solid surface interface to inhibit biofilm formation and reduce corrosion and MetaMx synthetic molecules that targets brain tumor initiating cells and invasive glioma cells. ARCH BIOPARTNERS is traded on TSX Venture Exchange in Canada. For more info on Arch Biopartners please contact Richard Muruve at 647 428 7031 or go to https://www.archbiopartners.com.

Arch Biopartners Outstanding Bonds

Arch Biopartners issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Arch Biopartners uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Arch bonds can be classified according to their maturity, which is the date when Arch Biopartners has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp Bond
US235822AB96		View
Volcan Compania Minera Corp Bond
USP98047AC08		View
Boeing Co 2196 Corp Bond
US097023DG73		View
HSBC Holdings PLC Corp Bond
US404280DR76		View
MPLX LP 52 Corp Bond
US55336VAL45		View
International Game Technology Corp Bond
US460599AD57		View
Morgan Stanley 3591 Corp Bond
US61744YAK47		View
MGM Resorts International Corp Bond
US552953CD18		View

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Arch Stock Analysis

When running Arch Biopartners' price analysis, check to measure Arch Biopartners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arch Biopartners is operating at the current time. Most of Arch Biopartners' value examination focuses on studying past and present price action to predict the probability of Arch Biopartners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arch Biopartners' price. Additionally, you may evaluate how the addition of Arch Biopartners to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY